Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

NCT03528902 is registered in ClinicalTrials.gov with Vanderbilt University Medical Center as lead sponsor.

NCT NCT03528902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03528902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
Lead sponsor
Vanderbilt University Medical Center
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2018
Completion date
June 14, 2023
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor antagonist, estrogens, familial primary pulmonary hypertension, hormone antagonists, hypertension, lung diseases, primary pulmonary hypertension, pulmonary arterial hypertension, tamoxifen